Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Genmab A/SNASDAQ: GMAB
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables grows 28.9% year over year
Q2 FY2026 accounts receivables of $259M (cash outflow) rose 28.9% year over year. Over 3 fiscal years it compounded at -57.2% a year.
Context
- Accounts receivables amounted to 4.5% of revenue in FY2025, down 2.9 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
Mixed currencies · from the cash flow
- Latest · FY2025
- (166.13M) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (166.13M) | — |
| FY2024 | 2024-12-31 | (1.59B) | -299.5% |
| FY2023 | 2023-12-31 | 797M | +137.5% |
| FY2022 | 2022-12-31 | (2.12B) | -97.7% |
| FY2021 | 2021-12-31 | (1.07B) | — |
Accounts Receivables vs competitors
How GMAB compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Accounts receivables amounts to 4.6% of revenue for GMAB, versus a peer median of 4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.89B EUR | +210.6% | -38.0% | 71.6% | |
| LTM Jun 2026 | $282.32M USD | +167.9% | +81.5% | 4.9% | |
| LTM Jun 2026 | $189.32M USD | — | -57.2% | 4.6% | |
| LTM Sep 2026 | $125.44M USD | +174128.2% | — | 9.2% | |
| LTM Sep 2026 | $40.23M USD | +265.9% | — | 10.6% | |
| LTM Jul 2026 | $29.86M USD | -128.6% | — | 1.2% | |
| LTM Jun 2026 | $12M USD | -7.7% | -76.6% | 10.3% | |
| LTM Mar 2026 | $516.86K USD | +106.0% | -41.0% | 0.7% | |
| LTM Mar 2026 | $117K USD | +103.5% | -41.7% | 0.1% | |
| LTM Dec 2025 | $0 USD | — | -50.9% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding GMAB) | — | +137.0% | -41.4% | 4.9% | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | 3.98B | 7.04B | 5.64B | 7.84B | 963.76M |
| Depreciation & Amortization | 248.99M | 362M | 293.62M | 413M | 71.06M |
| Deferred Income Tax | (546M) | 0 | 122M | 0 | 0 |
| Stock-Based Compensation | 310M | 439M | 586M | 721M | 0 |
| Change in Working Capital | (770M) | (1.93B) | 1.36B | (1.6B) | 225.18M |
| Accounts Receivables | (1.07B) | (2.12B) | 797M | (1.59B) | (166.13M) |
| Inventory | 0 | 0 | (57M) | (5M) | (9.01M) |
| Accounts Payables | 304M | 283M | 622M | 0 | 400.32M |
| Other Working Capital | 0 | (90M) | 0 | 0 | 0 |
| Other Non-Cash Items | (997.99M) | (1.99B) | (620.62M) | 388M | (73.06M) |
| Operating Cash Flow | 2.23B | 3.91B | 7.38B | 7.77B | 1.19B |
| Capital Expenditures | (252M) | (317M) | (376M) | (187M) | (37.03M) |
| Acquisitions (Net) | 709M | 2.44B | 0 | (12.25B) | (7.22B) |
| Purchases of Investments | (15.62B) | (9.7B) | (10.91B) | (8.64B) | (995.78M) |
| Sales of Investments | 14.91B | 7.25B | 10B | 11.28B | 2.62B |
| Other Investing Activities | (709M) | (2.44B) | (10M) | (117M) | 0 |
| Investing Cash Flow | (961M) | (2.76B) | (1.28B) | (9.91B) | (5.65B) |
| Debt Repayment | (58M) | (73M) | (91M) | (60M) | 5.23B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 23.02M |
| Common Stock Repurchased | (447M) | (908M) | (564M) | (3.99B) | (430.34M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 85M | 192M | 49M | 129M | (31.02M) |
| Financing Cash Flow | (420M) | (789M) | (606M) | (3.92B) | 4.79B |
| Effect of Forex Changes | 850M | 574M | (518M) | 1.05B | 13.06M |
| Net Change in Cash | 1.7B | 936M | 4.97B | (5.01B) | 345.33M |
| Free Cash Flow | 1.98B | 3.6B | 7B | 7.58B | 1.15B |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.